Comparing low-field MRI to high-field MRI for prostate cancer screening
Comparing Prostate Cancer Screening Between Standardized 3T MRI Screening Protocol and Low-Field MRI in a Prospective Study
University of Lausanne Hospitals · NCT06482489
This study is testing whether a lower-strength MRI can effectively screen for prostate cancer and provide good images compared to a stronger MRI.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 74 (estimated) |
| Ages | 18 Years and up |
| Sex | Male |
| Sponsor | University of Lausanne Hospitals (other) |
| Locations | 1 site (Lausanne, Canton of Vaud) |
| Trial ID | NCT06482489 on ClinicalTrials.gov |
What this trial studies
This study evaluates the effectiveness of low-field MRI (0.55T) compared to high-field MRI (3T) in screening for prostate cancer and improving image quality. It consists of three phases: first, optimizing the low-field MRI protocol with healthy volunteers; second, assessing image quality in patients with metallic implants; and third, evaluating low-field MRI in patients with suspicious prostate lesions identified on high-field MRI. The aim is to provide a more accessible and effective solution for prostate cancer screening while maintaining or enhancing image quality.
Who should consider this trial
Good fit: Ideal candidates include adult men aged 18 and older, particularly those with metallic implants or suspicious prostate lesions detected on high-field MRI.
Not a fit: Patients with a history of prostate cancer or those who cannot undergo MRI due to contraindications will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved prostate cancer screening methods that are more accessible for patients with metallic implants.
How similar studies have performed: While there have been studies on MRI effectiveness, this specific comparison of low-field and high-field MRI for prostate cancer screening is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: Work Package1 (WP): 0.55T MRI Protocol Development * Healthy male volunteers aged 18 and above. * Agree to be contacted for incidental findings * Signed informed consent WP2: 0.55T Prostate MRI with patients with metallic implant(s) * Adult men (≥18 y.o) with 3T MRI reported as sub-diagnostic due to metallic implants * Signed informed Consent WP3: 0.55T Prostate MRI with patients with suspicious lesion(s) * Adult men (≥18 y.o) * PI-RADS 4/5 lesions detected on 3T MRI, schedules for targeted biopsy * Signed informed consent Exclusion Criteria: WP1: 0.55T MRI Protocol Development * Individuals with a history of prostate cancer * MR Contraindications as listed in the MR Safety Screening form WP2: 0.55T Prostate MRI with patients with metallic implant(s) * Contraindications as per MD instructions * Any condition making the patient unsuitable for the study * Refusal to be notified in case of incidental finding on the examination WP3: 0.55T Prostate MRI with patients with suspicious lesion(s) * Individuals with a history of prostate cancer. * Contraindications as per MD instructions * Any condition making the patient unsuitable for the study * Refusal to be notified in case of incidental finding on the examination
Where this trial is running
Lausanne, Canton of Vaud
- Lausanne University Hospital — Lausanne, Canton of Vaud, Switzerland (RECRUITING)
Study contacts
- Study coordinator: Naïk Vietti-Violi, Dre
- Email: Naik-Vietti-Violi@chuv.ch
- Phone: 0795560240
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Prostate Cancer